thiophenes has been researched along with Bone Diseases, Metabolic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S; Pei, Y; Qiu, E; Shang, G; Wang, W; Wang, Y; Zhang, X; Zheng, K | 1 |
| Hamilton, JL; Ross, RD; Sumner, DR; Virdi, AS; Wilson, BM | 1 |
| Arantes, HP; Bilezikian, JP; Chiang, AY; Gimeno, SG; Lazaretti-Castro, M | 1 |
| Bruyere, O; Hiligsmann, M; Neuprez, A; Reginster, JY; Scholtissen, S | 1 |
| Cai, DH; Chen, H; Deng, WM; He, L; Li, QN; Sun, P; Yang, L | 1 |
| Aguirre, JI; Bryant, HU; Dalsky, GP; Harvey, A; Ma, YL; Moore, TL; Porras, LL; Sato, M; Shelbourn, TL; Wronski, TJ; Zeng, QQ | 1 |
| Davey, DA | 1 |
| Andersen, JE; Brüel, A; Raffalt, AC; Thomsen, JS; Vegger, JB | 1 |
| Bass, S; Diamond, T; Ebeling, P; Findlay, D; Flicker, L; MacLennan, A; Markwell, A; Nowson, C; O'Neill, S; Pocock, N; Sambrook, P; Singh, MF | 1 |
| Marie, PJ | 1 |
| Seeman, E | 1 |
| Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I | 1 |
| Cremers, S; Garnero, P | 1 |
| Bruyere, O; Malaise, O; Reginster, JY | 1 |
| Bowman, AR; Epstein, S; Jee, WS; Liang, H; Ma, YF; Marshall, I; Sass, DA | 1 |
| Inoue, T; Kushida, K; Li, X; Takahashi, M | 1 |
| Bryant, H; Drost, D; Fraher, LJ; Hock, J; Hodsman, AB; Holdsworth, D; Thornton, M; Watson, PH | 2 |
5 review(s) available for thiophenes and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Pharmacologic augmentation of implant fixation in osteopenic bone.
Topics: Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Combined Modality Therapy; Diphosphonates; Fracture Fixation; Fractures, Bone; Humans; Orthopedic Fixation Devices; Osseointegration; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prostheses and Implants; Thiophenes | 2014 |
Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Medication Adherence; Organometallic Compounds; Osteoarthritis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Thiophenes | 2008 |
Strontium as therapy for osteoporosis.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Humans; Organometallic Compounds; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Thiophenes | 2005 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors | 2006 |
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes | 2006 |
1 trial(s) available for thiophenes and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Strontium ranelate normalizes bone mineral density in osteopenic patients.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Dose-Response Relationship, Drug; Female; Humans; Longitudinal Studies; Organometallic Compounds; Osteogenesis; Thiophenes | 2007 |
12 other study(ies) available for thiophenes and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Therapeutic Effect of Strontium Ranelate on Bone in Chemotherapy-Induced Osteopenic Rats via Increased Bone Volume and Reduced Bone Loss.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcium; Male; Phosphorus; Rats; Rats, Sprague-Dawley; Thiophenes | 2019 |
Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial.
Topics: Age Distribution; Aged; Aged, 80 and over; Bone Diseases, Metabolic; Brazil; Calcium; Dietary Supplements; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures; Thiophenes; Vitamin D | 2016 |
Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glucocorticoids; Male; Methylprednisolone; Organometallic Compounds; Rats; Rats, Sprague-Dawley; Thiophenes | 2010 |
Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.
Topics: Alkaline Phosphatase; Anabolic Agents; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Dose-Response Relationship, Drug; Female; Femur; Gene Expression; Humans; Integrin-Binding Sialoprotein; Lumbar Vertebrae; Organometallic Compounds; Osteocalcin; Ovariectomy; Rats; Reverse Transcriptase Polymerase Chain Reaction; Teriparatide; Thiophenes; Time Factors | 2011 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Risedronic Acid; Spinal Fractures; Thiophenes | 2012 |
PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.
Topics: Alkaline Phosphatase; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Diseases, Metabolic; Female; Organ Size; Organometallic Compounds; Parathyroid Hormone; Rats; Rats, Wistar; Thiophenes; Tomography, X-Ray Computed | 2013 |
Guidelines for the management of postmenopausal osteoporosis for GPs.
Topics: Absorptiometry, Photon; Aged; Antihypertensive Agents; Benzothiadiazines; Biomarkers; Bone Diseases, Metabolic; Calcium; Diphosphonates; Diuretics; Drug Therapy, Combination; Estrogen Replacement Therapy; Family Practice; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Selective Estrogen Receptor Modulators; Sodium Chloride Symporter Inhibitors; Thiophenes; Vitamin D | 2004 |
Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Female; Humans; Organometallic Compounds; Osteoporosis, Postmenopausal; Spinal Fractures; Thiophenes | 2006 |
Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Cyclosporine; Drug Evaluation, Preclinical; Drug Synergism; Estrogen Antagonists; Estrogens; Female; Liver; Ovariectomy; Ovary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Thiophenes; Uterus | 1996 |
The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cholesterol; Estrogen Antagonists; Female; Humans; Injections, Subcutaneous; Lumbar Vertebrae; Osteocalcin; Ovariectomy; Pyrrolidines; Rats; Rats, Wistar; Thiophenes | 1998 |
The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Estrogen Antagonists; Female; Humans; Ovariectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Teriparatide; Thiophenes | 1999 |
Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Ovariectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Teriparatide; Thiophenes; Treatment Outcome | 1999 |